RecruitingPhase 1NCT06395285
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
A Phase Ib, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered DF-003 in ROSAH Syndrome Patients
Sponsor
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Enrollment
12 participants
Start Date
May 27, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria6
- Sufficient understanding of the purpose and procedures required for the study.
- Body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive.
- Genetic testing for ALPK1 mutations that has been shown to be associated with ROSAH syndrome (e.g. T237M or Y254C, or T237A mutations).
- Signs of uveitis (anterior and/or posterior) in the eye (e.g. macula edema, optic nerve edema, retinal vasculitis, or retinal vascular leakage).
- Patients must be deemed healthy except for diagnosis of ROSAH syndrome and its clinical manifestation.
- Patients must be at least 18 years of age but no older than 65 years of age at the time of Screening.
Exclusion Criteria20
- Males who plan to father a child or donate sperm while enrolled in this study or within 90 days after the last dose of study drug.
- Females who are pregnant, breastfeeding, planning to become pregnant, or planning to donate eggs while on study medication or within 90 days after the last dose of study drug.
- Use of any of the following prohibited medications:
- Agents that are known to have systemic anti-inflammatory responses or high risk for nephrotoxicity or hepatotoxicity
- Moderate CYP3A4 inhibitors: e.g., amiodarone, amprenavir, conivaptan, delavirdine, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, miconazole, verapamil, grapefruit juice, cat's claw (Dolichandra unguis-cati), Echinacea augustifolia, wild cherry, chamomile, licorice
- Strong CYP3A4 inhibitors: e.g., ceritinib, clarithromycin, cobicistat, elvitegravir/ritonavir, idelalisib, indinavir/ritonavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, paritaprevir/ritonavir, ombitasvir/paritaprevir/ritonavir (and/or dasabuvir), posaconazole, ritonavir, saquinavir/ritonavir, telithromycin, tipranavir/ritonavir, voriconazole.
- Strong CYP3A4 inducers: apalutamide, carbamazepine, enzalutamide, ivosidenib, lumacaftor/ivacaftor, mitotane, phenytoin, rifampin, St. John's wort.
- Digoxin
- Agents known to cause Torsade de Pointes: Disopyramide, procainamide, quinidine, sotalol, azithromycin, clarithromycin, erythromycin, ciprofloxacin, levofloxacin, moxifloxacin, fluconazole, ketoconazole, pentamidine, voriconazole, haloperidol, thioridazine, ziprasidone, citalopram, escitalopram, dolasetron, droperidol, granisetron, and ondansetron
- Investigational agents (small molecules and oligonucleotides), vaccines, or invasive medical devices within 28 days (4 weeks, or 5 half-lives, whichever is longer) prior to enrollment or having received a biological product within 6 months prior to enrollment.
- History of significant hypersensitivity to products related to DF-003 (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
- Recent (within 3 months prior to screening) or acute changes in the following laboratory values:
- Platelet count ≤ 120,000/mm3, or
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > ULN
- Bilirubin (total, direct) > ULN or
- International Normalization Ratio (INR) > ULN, or
- Serum albumin less than the lower limit of normal, or
- Estimated creatinine clearance < 70 mL/min/1.73 m2 at Screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, or
- Hemoglobin A1c (HbA1c) > 8%.
- Moderate or severe hepatic impairment (categorized as Child-Pugh class B and C, respectively, on the Child-Pugh Score for Cirrhosis Mortality)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDF-003
140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06395285